2.81
0.20 (7.66%)
| Previous Close | 2.61 |
| Open | 2.61 |
| Volume | 190,989 |
| Avg. Volume (3M) | 256,923 |
| Market Cap | 16,417,413 |
| Price / Book | 1.03 |
| 52 Weeks Range | |
| Earnings Date | 30 Mar 2026 |
| Diluted EPS (TTM) | -0.780 |
| Total Debt/Equity (MRQ) | 56.38% |
| Current Ratio (MRQ) | 0.540 |
| Operating Cash Flow (TTM) | -30.01 M |
| Levered Free Cash Flow (TTM) | -18.54 M |
| Return on Assets (TTM) | -178.72% |
| Return on Equity (TTM) | -916.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Reviva Pharmaceuticals Holdings | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -2.00 |
|
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer’s disease and Parkinson’s disease psychosis and its other drug candidate is RP1208. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.30% |
| % Held by Institutions | 20.35% |
| 52 Weeks Range | ||
| Median | 2.00 (-28.83%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 05 Jan 2026 | 2.00 (-28.83%) | Buy | 6.60 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jan 2026 | Announcement | Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia |
| 29 Dec 2025 | Announcement | Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |